Home
ATYR
ATYR News

Latest aTyr Pharma Inc. Common Stock (ATYR) News on October 24, 2024

Newsfile

10 days ago

aTyr Pharma to Present at the LD Micro Main Event XVII in October

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

GlobeNewswire

16 days ago

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

GlobeNewswire

22 days ago

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

aTyr Pharma to Participate in September Investor Conferences

GlobeNewswire

2 months ago

aTyr Pharma to Participate in September Investor Conferences

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

Simply Wall St.

2 months ago

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

GlobeNewswire

2 months ago

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

GlobeNewswire

3 months ago

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations

aTyr Pharma Announces Research Study with Stanford Medicine

GlobeNewswire

3 months ago

aTyr Pharma Announces Research Study with Stanford Medicine

Independent Director of aTyr Pharma Paul Schimmel Buys 10.0% More Shares

Simply Wall St.

3 months ago

Independent Director of aTyr Pharma Paul Schimmel Buys 10.0% More Shares

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

GlobeNewswire

3 months ago

aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company

Simply Wall St.

3 months ago

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company

Share on Social Networks: